New PD-MitoQUANT study published by CNRS researchers

Congratulations to Maya Bendifallah, Virginie Redeker, Elodie Monsellier, Luc Bousset*, Tracy Bellande, and Ronald Melki* for the publication of their recent study entitled: Interaction of the chaperones alpha B-crystallin and CHIP with fibrillar alpha-synuclein: Effects on internalization by cells and identification of interacting interfaces. The paper appeared in the journal Biochemical and Biophysical Research Communications on May 17, 2020. This is the sixth PD-MitoQUANT-referenced paper. Find the entire list, read the abstracts and download the pdfs of these open-access studies here. *PD-MitoQUANT PIs

May 25th, 2020|

COVID-19 Update

The current situation regarding the Coronavirus disease (COVID-19) is significantly impacting the research community, including the PD-MitoQUANT international consortium. We anticipate that the precise nature of these impacts will evolve over the coming weeks and months. Our institutions' priority is the safety and wellbeing of all people, including our own research teams. The consortium is working together to come up with solutions to reduce delays to the project as a result of the practical measures taken to contain the virus.

April 10th, 2020|

PD-MitoQUANT Partner Spotlight – H. Lundbeck A/S

With headquarters in Denmark, Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with brain diseases. For this purpose, Lundbeck is engaged in research, drug discovery development, manufacturing, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at disease areas within psychiatry and neurology. Within PD-MitoQUANT, Lundbeck: is scientific co-leader as part of the PD-MitoQUANT Executive Team, evaluates a range of α-synuclein (α-αSyn) fibril species to select the most promising for further investigation by the project, transfers their established α-Syn fibril primary neuron seeding assay to other partners, investigates mitophagy, transfers samples of α-Syn fibril seeded primary neurons to PD-MitoQUANT partner Radboud University Nijmegen Medical Centre for investigations of correlations between morphology and functionality, establishes the kinetics of the pathology development in a striatal stereotaxic α-Syn fibril injection mouse model to define the best timepoint for assessment of mitochondrial [...]

April 8th, 2020|

Meet Paula Scurfield, one of the PD-MitoQUANT PPI volunteers

The public, including patients, can and should be involved in all aspects of research, including study design, communication, and ethics. Patients bring unique knowledge and skills to projects, which can improve the quality of research. The Innovative Medicines Initiative encourages public and patient involvement (PPI) in all of its projects. PD-MitoQUANT is fortunate to have two people with Parkinson’s involved in the project through our patient advocacy partner Parkinson’s UK. Here, we meet Paula Scurfield. Paula was diagnosed with Parkinson’s in March 2014 and is the fourth person in her family to have the condition. Before retirement 10 years ago, Paula worked as a geography teacher and part-time university lecturer in Hong Kong, Washington DC, Beijing, the Maldives, and the UK. She believes that volunteering and taking part in clinical trials is empowering, enabling her to meet the challenges of living with an incurable neurodegenerative disorder head-on. When not travelling, [...]

March 31st, 2020|

Richard Campbell, Parkinson’s UK volunteer, blogs about his involvement in PD-MitoQUANT

PD-MitoQUANT is fortunate to have two people with Parkinson’s, Richard Campbell and Paula Scurfield, involved in the project through our patient advocacy partner Parkinson’s UK ( Recently, Richard wrote a blog entitled “Getting involved in an international research project on Parkinson’s”. "Paula Scurfield and I are part of the Parkinson’s UK Research Support Network and have joined the project as patient and public representatives. Our role is to advise on how information about the project is communicated, and how findings are shared with the Parkinson’s community and the public. I became interested in the research because of its more basic science approach to Parkinson’s. There are many opportunities to take part in research testing new drugs and treatments for Parkinson’s, including on-line surveys. However, this was an opportunity to look in detail at some of the possible causes of the condition in terms of genetics, cell structure and organisation, and the early [...]

March 25th, 2020|
Go to Top